424 related articles for article (PubMed ID: 11971121)
1. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis.
Dhib-Jalbut S
Neurology; 2002 Apr; 58(8 Suppl 4):S3-9. PubMed ID: 11971121
[TBL] [Abstract][Full Text] [Related]
2. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Johnston J; So TY
Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
[TBL] [Abstract][Full Text] [Related]
3. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
4. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
5. Glatiramer acetate for the treatment of multiple sclerosis.
Wolinsky JS
Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis.
Zhang J; Hutton G; Zang Y
Clin Ther; 2002 Dec; 24(12):1998-2021. PubMed ID: 12581542
[TBL] [Abstract][Full Text] [Related]
7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
8. Considerations in the treatment of relapsing-remitting multiple sclerosis.
Calabresi PA
Neurology; 2002 Apr; 58(8 Suppl 4):S10-22. PubMed ID: 11971122
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
Mahurkar S; Suppiah V; O'Doherty C
Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
[TBL] [Abstract][Full Text] [Related]
10. Lessons from randomised direct comparative trials.
Achiron A; Fredrikson S
J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
[TBL] [Abstract][Full Text] [Related]
11. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis.
Zang Y; Hong J; Robinson R; Li S; Rivera VM; Zhang JZ
J Neuroimmunol; 2003 Apr; 137(1-2):144-53. PubMed ID: 12667659
[TBL] [Abstract][Full Text] [Related]
12. Risk-benefit assessment of glatiramer acetate in multiple sclerosis.
Ziemssen T; Neuhaus O; Hohlfeld R
Drug Saf; 2001; 24(13):979-90. PubMed ID: 11735654
[TBL] [Abstract][Full Text] [Related]
13. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.
Yong VW
Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
Scott LJ
CNS Drugs; 2013 Nov; 27(11):971-88. PubMed ID: 24129744
[TBL] [Abstract][Full Text] [Related]
15. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
Galetta SL; Markowitz C; Lee AG
Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
[TBL] [Abstract][Full Text] [Related]
17. Factors leading patients to discontinue multiple sclerosis therapies.
Daugherty KK; Butler JS; Mattingly M; Ryan M
J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
[TBL] [Abstract][Full Text] [Related]
18. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
19. Disease modifying treatment in multiple sclerosis.
Fuller GN; Bone I
J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
[No Abstract] [Full Text] [Related]
20. Interferon beta and glatiramer acetate therapy.
McGraw CA; Lublin FD
Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
